Free Trial
NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ALBO stock logo

About Albireo Pharma Stock (NASDAQ:ALBO)

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

ALBO Stock News Headlines

Prospect Park II in Fort Lauderdale
ALBO Historical Data
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
ALBO.PH - | Stock Price & Latest News | Reuters
Why These Two Biotech Stocks Blasted Higher This Week
Expert Ratings for Albireo Pharma
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
6/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives


ALBO Stock Analysis - Frequently Asked Questions

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period in the previous year, the company earned ($1.96) EPS.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

This page (NASDAQ:ALBO) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners